73 results
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
, and on April 26, 2024, we effected a 75-for-1 reverse split of our Common Stock.
Common Stock
Voting Rights
Holders of our Common Stock are entitled to one … vote for each share held on all matters submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
, every 75 shares of the Company’s pre-reverse split common stock was combined and reclassified as one share of common stock. Proportionate voting rights … submitted to a vote of stockholders and do not have cumulative voting rights. An election of directors by our stockholders shall be determined
8-K
EX-4.3
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
as Stockholder until Exercise; No Settlement in Cash. This Warrant does not entitle the Holder to any voting rights, dividends or other rights
8-K
EX-4.2
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
8-K
EX-4.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except
8-K
4mpya 2vd5j4w
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
8-K
th9405r locf8lr
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
424B3
fqi208w z7s
2 Feb 24
Prospectus supplement
12:00am
DEF 14C
wmhgu8mkpii
29 Jan 24
Information statement
8:00am
PRE 14C
mguisu23 6a
17 Jan 24
Preliminary information
5:05pm
8-K
txxeh06
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
8jlfmn62ttk1198 oc
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.2
tm12j0v
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
EX-4.1
98xbwl
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.2
gz6ev
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.3
9w05xj1yak i0wseg5
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
w6n11 xxgbctbt5owa
2 Nov 23
Prospectus supplement with pricing info
9:00am